Patent application number | Description | Published |
20120088747 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF - Compounds, compositions and methods for treating GHS-R mediated disorders are described herein. | 04-12-2012 |
20120122849 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER - Compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of cancer. | 05-17-2012 |
20120122885 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 05-17-2012 |
20130035329 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. | 02-07-2013 |
20130190287 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. | 07-25-2013 |
20140011804 | BICYCLIC PKM2 ACTIVATORS - Compounds and compositions comprising compounds including formula (I) that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer. | 01-09-2014 |
20140073625 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS - Compounds of general Formula (I), and compositions comprising compounds of general formula I that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 03-13-2014 |
20140142081 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 05-22-2014 |
20140142146 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 05-22-2014 |
20140206673 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds of formula (I), wherein X, Y, Z, W, V, R | 07-24-2014 |
20140213580 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds. | 07-31-2014 |
20140249196 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARĪ³), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 09-04-2014 |
20140288090 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARĪ³), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 09-25-2014 |
20140323467 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 10-30-2014 |
20140323729 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 10-30-2014 |
20150087600 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 03-26-2015 |